New commercial agreement with large pharma | 03-May-2024 | 07:00 | RNS |
New commercial agreement with AstraZeneca | 24-Apr-2024 | 07:00 | RNS |
US and EU patents for innovative CellKeep™... | 22-Apr-2024 | 07:00 | RNS |
Standard form for notification of major holdings | 10-Jan-2024 | 12:57 | RNS |
Breakthrough clinical results | 04-Jan-2024 | 07:00 | RNS |
Contract announcement with Eisai Inc. | 02-Jan-2024 | 07:00 | RNS |
Broker Announcement | 11-Dec-2023 | 07:00 | RNS |
Trading and business update | 09-Nov-2023 | 07:00 | RNS |
Interim Results for the period ended 30 June 2023 | 07-Sep-2023 | 07:00 | RNS |
ANGLE notice of interim results | 15-Aug-2023 | 07:00 | RNS |
Result of 2023 Annual General Meeting | 28-Jun-2023 | 16:54 | RNS |
Standard form for notification of major holdings | 27-Jun-2023 | 12:24 | RNS |
Pharma services contract with Artios Pharma | 25-May-2023 | 07:00 | RNS |
Board change - appointment of new Chairman | 22-May-2023 | 07:00 | RNS |
Results for the year ended 31 December 2022 | 21-Apr-2023 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 17.75p |
Change Today | 4.00p |
% Change | 29.09 % |
52 Week High | 31.40 |
52 Week Low | 9.25 |
Volume | 7,404,983 |
Shares Issued | 260.58m |
Market Cap | £46.25m |
RiskGrade | 312 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 1 |
Buy | 0 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
16:28 | 150,000 @ 17.65p |
14:40 | 100,000 @ 17.00p |
16:29 | 10,000 @ 18.06p |
16:29 | 35,000 @ 18.30p |
16:29 | 15,000 @ 17.88p |
CEO | Andrew D Newland |
Finance Director | Ian F Griffiths |
Chair | Jan Groen |
You are here: research